Detalhe da pesquisa
1.
Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.
Clin Infect Dis
; 62(12): 1497-1504, 2016 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26936665
2.
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response.
Hepatology
; 60(4): 1187-95, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25065814
3.
Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection.
World J Hepatol
; 9(11): 551-561, 2017 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-28469811
4.
Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results.
World J Virol
; 6(4): 59-72, 2017 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29147645
5.
Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.
World J Gastroenterol
; 22(9): 2844-54, 2016 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26973423
6.
Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Monoinfection Treatment.
Gastroenterol Hepatol (N Y)
; 10(11): 706-715, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28435407